Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Daniel Muteba"'
Autor:
Jean-Claude Makenga Bof, Daniel Muteba, Paul Mansiangi, Félicien Ilunga-Ilunga, Yves Coppieters
Publikováno v:
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the freq
Externí odkaz:
https://doaj.org/article/9b3646f88d074417a97e403262bd200c
Autor:
Jean-Claude Makenga Bof, Fortunat Ntumba Tshitoka, Daniel Muteba, Paul Mansiangi, Yves Coppieters
Publikováno v:
Tropical Medicine and Infectious Disease, Vol 4, Iss 2, p 92 (2019)
Here, we review all data available at the Ministry of Public Health in order to describe the history of the National Program for Onchocerciasis Control (NPOC) in the Democratic Republic of the Congo (DRC). Discovered in 1903, the disease is endemic i
Externí odkaz:
https://doaj.org/article/d8d750b17527488890e0f8fcd24042b0
Autor:
Francis Anto, Didier Bakajika, Daniel Muteba, Sarah Hailemariam, Célestin N. Nsibu, Didier Nzolo, Gautier Mesia, Jean-Claude Makenga, Samuel M. Mampunza, G. L. Tona
Publikováno v:
Drugs-Real World Outcomes
Drugs-Real World Outcomes, 4 (3
Drugs-Real World Outcomes, 4 (3
Introduction: The mainstay of onchocerciasis control currently is mass administration of ivermectin; however, this may be associated with serious adverse events, including deaths, when administered in areas where onchocerciasis and loiasis are co-end
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bae769537a4e980a4a745c43a906f207
http://europepmc.org/articles/PMC5567455
http://europepmc.org/articles/PMC5567455
Autor:
Yves Coppieters, Félicien Ilunga-Ilunga, Daniel Muteba, Paul Mansiangi, Jean-Claude Makenga Bof
Publikováno v:
BMC Pharmacology and Toxicology, 20 (1
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 20, Iss 1, Pp 1-10 (2019)
BMC Pharmacology & Toxicology
The progress of mass, community-directed, treatment with ivermectin (CDTI) for onchocerciasis control was disrupted by severe adverse effects (SAE) in the Democratic Republic of Congo (DRC). The study aimed at determining the frequency of post-CDTI S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5805d9933a6812e4388e2e776d39c0a
https://doi.org/10.1186/s40360-019-0327-5
https://doi.org/10.1186/s40360-019-0327-5